相关实验视频

Updated: Feb 18, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

对寡进性转移性RCC的立体性废除性辐射疗法:长期系统治疗益处的预测因素

Lucian Zhao¹, Dana Keilty², Soumyajit Roy³

¹Department of Radiation Oncology, Simmons Comprehensive Cancer Center, Dallas, Texas.

International journal of radiation oncology, biology, physics

|February 16, 2026

概括

在全身疗法 (ST) 期间,对转移性细胞癌 (mRCC) 的寡头进展进行立体性除性放射疗法 (SAbR),可提供高局部控制. 患有单个进展性病变的患者表现最好,支持SAbR作为节约资源的策略.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

在全身疗法 (ST) 期间,立体性废除性放射疗法 (SAbR) 越来越多地用于转移性细胞癌 (mRCC) 的寡头进展.
确定从SAbR中获益最多的患者子组对于治疗优化至关重要.

研究的目的:

评估在ST期间OP-mRCC患者SAbR的疗效和结果.
确定最有可能从SAbR治疗中受益的患者子组.

主要方法:

对96名OP-mRCC患者的回顾性分析,这些患者用SAbR治疗了153个病变 (2010-2023年).
新的终点:改性无进展生存率 (mPFS) 从SAbR转向ST转换或死亡.
系统治疗升级 (E-ST) 作为竞争风险的评估,以及整体存活率 (OS),局部控制和毒性.

主要成果:

平均mPFS为9.2个月; 一年估计为38%.
患有2-5种进展性病变的患者与患有1种病变的患者相比,ST转换或死亡的风险明显更高.
较高的局部控制 (93%),最小的3级毒性;免疫疗法使用显示出改善mPFS的非显著趋势.

结论:

在OP-mRCC中,SAbR是有效的,提供高局部控制和延迟ST升级,特别是在单个进展性病变的患者中.
在mRCC管理中,SAbR支持一种节约资源,以患者为中心的策略.
需要进行前性研究来证实SAbR与免疫治疗结合的潜在益处.

更多相关视频

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...